By John Q. Hosedrinker 
The Supreme Court has ruled in favor of the maker of Roundup weedkiller, potentially blocking thousands of lawsuits that alleged the product causes cancer. In a 7-2 decision, the court determined that the company cannot be sued in state courts for failure to warn, as federal regulations have deemed a cancer link unlikely and do not mandate such a warning. This decision is seen as a victory for Bayer, the company that acquired Roundup, and its argument that it must adhere to federal standards. While this ruling is expected to impact ongoing litigation, Bayer plans to proceed with a proposed $7.25 billion class-action settlement.
Read the original article here
The Supreme Court has recently issued a significant 7-2 ruling that effectively blocks thousands of lawsuits against the maker of Roundup weedkiller. This decision hinges on the premise that federal regulations have deemed a direct link between Roundup’s key ingredient, glyphosate, and cancer to be unlikely. Consequently, the ruling states that the company cannot be sued in state courts over these claims, as there was no federal requirement for a warning label due to this assessment of low risk.
This outcome comes amidst ongoing and heated debate regarding the potential health effects of glyphosate, the active component in Roundup. It’s worth noting that in 2015, the World Health Organization’s International Agency for Research on Cancer classified glyphosate as “probably carcinogenic to humans.” This designation creates a clear divergence from the stance taken by the U.S. Environmental Protection Agency (EPA), which has concluded that glyphosate is not likely to cause cancer in humans when used according to its intended instructions.
The core of the Supreme Court’s decision appears to be rooted in this federal determination. If federal regulations, in their assessment, find a cancer link to be improbable, then establishing a direct causal relationship between a consumer’s cancer and the use of Roundup becomes an exceedingly difficult legal hurdle. Without a clear federal finding of risk or a mandated warning label, proving that the company *should have known* and therefore warned consumers about a cancer risk becomes a much more complex, if not impossible, argument to make in state courts.
This legal interpretation raises some critical questions about how to reconcile differing scientific opinions and regulatory approaches. The existence of a “probably carcinogenic” designation from a respected international body like the WHO, juxtaposed with the EPA’s more lenient assessment, highlights the complexities of scientific consensus and regulatory policy. For individuals seeking to sue, the challenge now is bridging this gap and demonstrating a direct harm that the federal authorities have not officially recognized as probable.
The ruling has been met with considerable backlash, with many expressing profound disappointment and anger. A prevailing sentiment is that the decision prioritizes corporate interests over public health and safety. Critics argue that this outcome exemplifies a pattern of the Supreme Court favoring corporations and the wealthy, often at the expense of ordinary citizens. The idea that “profits over people” is driving such decisions is a common refrain, particularly among those who feel that the court’s composition and rulings consistently serve to benefit businesses.
There are also concerns that this decision could be viewed as a victory for deregulation and an administration that has been perceived as being too closely aligned with corporate interests. The suggestion that “federal regulations” might have been influenced by deregulation efforts or that there might be an appearance of undue influence between companies and regulatory bodies like the EPA adds another layer of concern for those already skeptical of the ruling.
The historical context of companies like Monsanto (now part of Bayer, the maker of Roundup) and their past practices in certain communities, where they have been accused of environmental contamination and a lack of accountability, also fuels the current distrust. The narrative of companies moving to areas with less stringent regulations and leaving behind toxic legacies resonates with many who see this Supreme Court ruling as a continuation of a pattern of unchecked corporate power.
Ultimately, this Supreme Court ruling significantly complicates the ability of individuals who believe they have been harmed by Roundup to seek legal recourse. While the debate over glyphosate’s carcinogenicity continues, the court’s decision has provided a substantial legal shield for the manufacturer, at least in state courts. For those affected, and for many observers, this outcome represents a deeply disheartening moment, reinforcing anxieties about justice, corporate responsibility, and the prioritization of economic interests in the legal and regulatory landscape. The question remains: what does this mean for public health and accountability moving forward?